About Helen O’Neill

My academic research is focused on the use of CRISPR genome editing and base editing for the potential treatment of disorders.
I am passionate about women’s health, education and research.
Current Director for the MSc in Reproductive Science and Women’s Health at University College London.

I am CEO and founder of Hertility Health, an innovative healthcare tech company on a mission to give women the ability to track their fertility and reproductive health. Research is the focus of our initiative through a machine-learning driven healthcare solution which integrates both a symptom checker and biomarker testing, delivered to the door.
We tailor each woman’s individual hormone panel by taking into account her reproductive and medical history. We, therefore, ensure that testing, route-to-diagnosis and care is accurate, accessible and affordable.
We are excited to be the first to offer a 360-degree view into each individual woman’s health and will build on this exponentially to have an inclusive, comprehensive dataset of female pathologies, genetics and biomarkers, enabling ever-learning algorithms to aid remote research and innovation for diagnostics and care.
We are using deep learning to identify women’s increased risk of fertility deterioration and to prompt clinicians to consider more intensive monitoring and interventions.

With at-home blood test, paired with bespoke testing, actionable advice and a route-to-care, we help women learn more about their own biology and plan accordingly. We are tackling the gender data gap through personalised medicine in reproductive health.